




RealRate

# PHARMACEUTICAL 2018

## VERTEX PHARMACEUTICALS INC MA Rank 126 of 342



RealRate

The First AI Rating Agency

www.realrate.ai



# PHARMACEUTICAL 2018

## VERTEX PHARMACEUTICALS INC MA Rank 126 of 342



The relative strengths and weaknesses of VERTEX PHARMACEUTICALS INC MA are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VERTEX PHARMACEUTICALS INC MA compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 92% points. The greatest weakness of VERTEX PHARMACEUTICALS INC MA is the variable Assets, Current, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 146%, being 100% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	2,648,963
Cost of Goods Sold	0
Intangible Assets	50,384
Liabilities, Current	807,260
Liabilities, Non-Current	26,048
Other Assets	57,230
Other Compr. Net Income	139,104
Other Expenses	437,381
Other Liabilities	670,400
Other Net Income	-138,932
Other Revenues	2,488,652
Property and Equipment	789,437
Research and Development	1,324,625
Selling, General and Administrative Expense	496,079

Output Variable	Value in 1000 USD
Assets	3,546,014
Liabilities	1,503,708
Expenses	2,258,085
Revenues	2,488,652
Stockholders Equity	2,042,306
Net Income	91,635
Comprehensive Net Income	161,187
Economic Capital Ratio	146%